Actively Recruiting

Phase Not Applicable
Age: 12Years +
All Genders
NCT05865119

OPTImal Treatment of Sinus VENOSUS Defect

Led by Centre Chirurgical Marie Lannelongue · Updated on 2023-08-14

60

Participants Needed

13

Research Sites

313 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Sinus venosus defect (SVD) accounts for 10% of atrial septal defects and is characterized by an anomalous pulmonary venous return in the superior vena cava associated with a high situated atrial septal defect. Since 2013, transcatheter correction of this congenital heart disease has emerged as a new treatment option. The procedure involves placement of a covered stent in the superior vena cava that tunnels the anomalous pulmonary venous return to the left atrium. Preliminary results are limited but promising. The devices to be used depend on anatomic considerations. XXL stents than 70mm are often required. Today, the availability of CE marked stents is limited. There have been recent reports of successful corrections with the specifically developed Optimus XXL 100mm covered stent (ANDRATEC) with compassionate approval from the Agence Nationale de Sûreté du Médicament in France. Setting up a feasibility study to investigate the use of medical devices in this indication was required. The objective of this project is to study the feasibility, efficacy and safety of the Optimus stent in this newly developed transcatheter procedure, in comparison with the gold-standard surgical method. A French national multicenter comparative cohort study including all eligible patients referred for transcatheter correction of SVD was designed. The feasibility of the transcatheter procedures will be investigated beforehand by virtual digital simulation and simulation on a 3D printed model. The procedures will then be performed in centers of the M3C network for complex congenital heart diseases (CARDIOGEN). The primary endpoint will be a composite of efficacy, defined as complete occlusion of the shunt, and safety, defined as the absence of major events at 6 months. The secondary endpoints will be anatomical, functional and psychosocial (quality of life). It is expected that transcatheter treatment gives comparable results to surgery on the primary endpoint. This could justify the further development of this procedure as an alternative to surgery and facilitate the validation of dedicated equipment.

CONDITIONS

Official Title

OPTImal Treatment of Sinus VENOSUS Defect

Who Can Participate

Age: 12Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • At least 12 years old
  • Have sinus venosus defect (SVD) with right ventricular end-diastolic volume enlargement as defined by guidelines
  • Indicated for atrial septal defect correction based on medical-surgical meeting and ESC 2020 criteria
  • Adult patients who have received study information and signed consent
  • Minor patients with no opposition from both parents for data use
  • Agree to be followed for the study duration
  • Affiliated with or beneficiary of a social security plan
  • Minor patients are eligible only for surgical treatment and included descriptively
Not Eligible

You will not qualify if you...

  • Under guardianship, curatorship, or judicial protection
  • Deprived of liberty
  • Pregnant or breastfeeding women
  • Currently enrolled in another interventional research study

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 13 locations

1

CHU Bordeaux

Bordeaux, France, 33404

Not Yet Recruiting

2

Hospices Civils de Lyon

Bron, France, 69500

Not Yet Recruiting

3

CHU Clermont-Ferrand

Clermont-Ferrand, France, 63000

Not Yet Recruiting

4

CHU Grenoble

Grenoble, France, 38700

Actively Recruiting

5

Sébastien HASCOËT

Le Plessis-Robinson, France, 92350

Actively Recruiting

6

CHU Lille

Lille, France, 59000

Actively Recruiting

7

Hôpitaux universitaire de Marseille

Marseille, France, 13385

Not Yet Recruiting

8

CHU Nantes

Nantes, France, 44000

Not Yet Recruiting

9

CHU Necker APHP Paris

Paris, France, 75015

Not Yet Recruiting

10

HEGP Paris

Paris, France, 75015

Not Yet Recruiting

11

CHU Toulouse

Toulouse, France, 31300

Not Yet Recruiting

12

Clinique Pasteur, Toulouse

Toulouse, France, 31300

Not Yet Recruiting

13

CHU Tours

Tours, France, 37000

Not Yet Recruiting

Loading map...

Research Team

S

SEBASTIEN HASCOËT

CONTACT

F

FLORENCE LECERF

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here